LE WE PMID CA
Belimumab ttBLyS8960Belimumab ttBLyS

81C6 ttTenascin

Abatacept ttCTLA4Conjugate

Abciximab ttGPIIAIIIB

Adalimumab ttTNFalpha

AIN457

Alefacept

Alemtuzumab ttCD52

AMG386 ttAngiopoietin1 ttAngiopoietin2

Antibodies (therapeutic use)

Atacicept ttBlys ttAPRIL

BAFF

Bapineuzumab ttAmyloidBeta

Basiliximab ttIL2R

Belatacept ttCD80 ttCD86

Belimumab ttBLyS

Bevacizumab ttVEGF

BLYS

Brentuximab vedotin ttCD30

Briakinumab ttIL12 ttIL23

Canakinumab ttIL1beta

Catumaxomab ttEpCAM ttCD3 linkerAb

Certolizumab ttTNFalpha

Cetuximab ttEGFR

Daclizumab ttIL2R

Dalotuzumab ttIGF1R

Denosumab ttRANKL

Eculizumab ttFactorH

Efalizumab ttLFA1

Epratuzumab ttCD22

Etanercept ttTNFalpha

FactorIXFc ttFactorIX

FactorVIIIFc ttFactorVIII

Farletuzumab ttFolateRalpha

Figitumumab ttIGF1R

Galiximab ttCD80

Gemtuzumab ozogamicin ttCD33

Girentuximab ttCarbonicAnhydraseIX

Golimumab ttTNFalpha

Ibritumomab tiuxentan yttrium ttCD20

Immunosuppressive agents

Infliximab ttTNFalpha

Inotuzumab ozogamicin ttCD22

Ipilimumab ttCTLA4

Mepolizumab ttIL5

Motavizumab ttRSVirus

MuromonabCD3 ttCD3

Naptumomab estafenatox tt5T4

Natalizumab ttIntegrinalpha4

Necitumumab ttEGFR

Nimotuzumab ttEGFR

Obinutuzumab ttCD20

Ocrelizumab ttCD20

Ofatumumab ttCD20

Omalizumab ttCD20

Otelixizumab ttCD3

Pagibaximab ttLipoteichoicAcidStaphlococcus

Palivizumab ttRSVirusFprotein

Panitumomab ttEGFR

Pertuzumab ttHER2

QPI1002 ttp53

Ramucirumab ttVEGFR2

Ranibizumab ttVEGF

Raxibacumab ttAnthrax

REGN88 ttIL6R

Repertaxin ttCXCR1 ttCXCR2

Reslizumab ttIL5

Rilonacept ttIL1R

Rituximab ttCD20

RPSGLIG ttPSelectin

Solanezumab ttAmyloidBeta

Systemic lupus erythematosus

T1H ttCD6

Tanezumab ttNGF

Teplizumab ttCD3

Tocilizumab ttIL6

Tositumomab ttCD20

TP10 ttsCR3

Transplantation

Trastuzumab emtansine ttHER2

Trastuzumab ttHER2

Tremelimumab ttCLTA4

Ustekinumab ttIL12 ttIL23

Vedolizumab ttIntegrina4b7

Zalutumumab ttEGFR

Zanulimumab ttCD4

2010  
1
Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?
[21122473] Discov Med 10(54): 416-24 (2010)
2011  
2
Antibody-based therapeutics to watch in 2011.
[21051951] MAbs 3(1): 76-99 (2011)
2010  
3
Antibody immunosuppressive therapy in solid organ transplant: Part II.
[20948291] MAbs 2(6): 607-12 (2010)
2010  
4
Antibodies to watch in 2010.
[20065640] MAbs 2(1): 84-100 (2010)
2011  
5
An update on belimumab for the treatment of lupus.
[21383914] Biologics 5(-): 33-43 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Belimumab ttBLyS

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia